These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1277 related articles for article (PubMed ID: 20119473)

  • 1. Protocol for accuracy of point of care (POC) or in-office urine drug testing (immunoassay) in chronic pain patients: a prospective analysis of immunoassay and liquid chromatography tandem mass spectometry (LC/MS/MS).
    Manchikanti L; Malla Y; Wargo BW; Cash KA; Pampati V; Damron KS; McManus CD; Brandon DE
    Pain Physician; 2010; 13(1):E1-E22. PubMed ID: 20119473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative evaluation of the accuracy of immunoassay with liquid chromatography tandem mass spectrometry (LC/MS/MS) of urine drug testing (UDT) opioids and illicit drugs in chronic pain patients.
    Manchikanti L; Malla Y; Wargo BW; Fellows B
    Pain Physician; 2011; 14(2):175-87. PubMed ID: 21412372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative evaluation of the accuracy of benzodiazepine testing in chronic pain patients utilizing immunoassay with liquid chromatography tandem mass spectrometry (LC/MS/MS) of urine drug testing.
    Manchikanti L; Malla Y; Wargo BW; Fellows B
    Pain Physician; 2011; 14(3):259-70. PubMed ID: 21587329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urine drug testing in chronic pain.
    Christo PJ; Manchikanti L; Ruan X; Bottros M; Hansen H; Solanki DR; Jordan AE; Colson J
    Pain Physician; 2011; 14(2):123-43. PubMed ID: 21412368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An evaluation of the diagnostic accuracy of liquid chromatography-tandem mass spectrometry versus immunoassay drug testing in pain patients.
    Pesce A; Rosenthal M; West R; West C; Crews B; Mikel C; Almazan P; Latyshev S
    Pain Physician; 2010; 13(3):273-81. PubMed ID: 20495592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of oral fluid in compliance monitoring of opioid medications.
    Conermann T; Gosalia AR; Kabazie AJ; Moore C; Miller K; Fetsch M; Irvan D
    Pain Physician; 2014; 17(1):63-70. PubMed ID: 24452646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of clonazepam compliance by measurement of urinary concentration by immunoassay and LC-MS/MS in pain management population.
    West R; Pesce A; West C; Crews B; Mikel C; Almazan P; Rosenthal M; Latyshev S
    Pain Physician; 2010; 13(1):71-8. PubMed ID: 20119465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A critical assessment of opioid treatment adherence using urine drug testing in chronic pain management.
    McCarberg BH
    Postgrad Med; 2011 Nov; 123(6):124-31. PubMed ID: 22104461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic monitoring of benzodiazepines in the management of pain: current limitations of point of care immunoassays suggest testing by mass spectrometry to assure accuracy and improve patient safety.
    Mikel C; Pesce AJ; Rosenthal M; West C
    Clin Chim Acta; 2012 Aug; 413(15-16):1199-202. PubMed ID: 22484396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KIMS, CEDIA, and HS-CEDIA immunoassays are inadequately sensitive for detection of benzodiazepines in urine from patients treated for chronic pain.
    Darragh A; Snyder ML; Ptolemy AS; Melanson S
    Pain Physician; 2014; 17(4):359-66. PubMed ID: 25054395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic pain: reducing costs through early implementation of adherence testing and recognition of opioid misuse.
    McCarberg BH
    Postgrad Med; 2011 Nov; 123(6):132-9. PubMed ID: 22104462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lower Cutoffs for LC-MS/MS Urine Drug Testing Indicates Better Patient Compliance.
    Krock K; Pesce A; Ritz D; Thomas R; Cua A; Rogers R; Lipnick P; Kilbourn K
    Pain Physician; 2017 Nov; 20(7):E1107-E1113. PubMed ID: 29149155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does random urine drug testing reduce illicit drug use in chronic pain patients receiving opioids?
    Manchikanti L; Manchukonda R; Pampati V; Damron KS; Brandon DE; Cash KA; McManus CD
    Pain Physician; 2006 Apr; 9(2):123-9. PubMed ID: 16703972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Benefits of Direct-to-Definitive Testing for Monitoring Compliance in Pain Management.
    Gencheva R; Petrides A; Kantartjis M; Tanasijevic M; Dahlin JL; Melanson S
    Pain Physician; 2018 Nov; 21(6):E583-E592. PubMed ID: 30508989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoassay in healthcare testing applications.
    DePriest AZ; Black DL; Robert TA
    J Opioid Manag; 2015; 11(1):13-25. PubMed ID: 25750161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of the Current State of Urine Drug Testing in Chronic Pain: Still Effective as a Clinical Tool and Curbing Abuse, or an Arcane Test?
    Chakravarthy K; Goel A; Jeha GM; Kaye AD; Christo PJ
    Curr Pain Headache Rep; 2021 Feb; 25(2):12. PubMed ID: 33598816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interpretation of urine drug testing results in patients using transdermal buprenorphine preparations for the treatment of chronic noncancer pain.
    Markman JD; Barbosa WA; Gewandter JS; Frazer M; Rast S; Dugan M; Nandigam K; Villareal A; Kwong TC
    Pain Med; 2015 Jun; 16(6):1132-6. PubMed ID: 25800409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urine drug screening: a valuable office procedure.
    Standridge JB; Adams SM; Zotos AP
    Am Fam Physician; 2010 Mar; 81(5):635-40. PubMed ID: 20187600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDA/DEA/PDMP/UDT: alphabet soup or sensible and integrated risk management?
    Passik SD; Kirsh KL; Twillman RK
    J Opioid Manag; 2015; 11(1):77-81. PubMed ID: 25750168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2--guidance.
    Manchikanti L; Abdi S; Atluri S; Balog CC; Benyamin RM; Boswell MV; Brown KR; Bruel BM; Bryce DA; Burks PA; Burton AW; Calodney AK; Caraway DL; Cash KA; Christo PJ; Damron KS; Datta S; Deer TR; Diwan S; Eriator I; Falco FJ; Fellows B; Geffert S; Gharibo CG; Glaser SE; Grider JS; Hameed H; Hameed M; Hansen H; Harned ME; Hayek SM; Helm S; Hirsch JA; Janata JW; Kaye AD; Kaye AM; Kloth DS; Koyyalagunta D; Lee M; Malla Y; Manchikanti KN; McManus CD; Pampati V; Parr AT; Pasupuleti R; Patel VB; Sehgal N; Silverman SM; Singh V; Smith HS; Snook LT; Solanki DR; Tracy DH; Vallejo R; Wargo BW;
    Pain Physician; 2012 Jul; 15(3 Suppl):S67-116. PubMed ID: 22786449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 64.